Home » Stocks » Palatin Technologies

Palatin Technologies, Inc. (PTN)

Stock Price: $0.590 USD 0.013 (2.32%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $0.590 -0.001 (-0.09%) Aug 3, 8:00 PM

Stock Price Chart

Key Info

Market Cap 135.26M
Revenue (ttm) 60.38M
Net Income (ttm) 37.10M
Shares Out 229.26M
EPS (ttm) 0.15
PE Ratio 3.93
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $0.590
Previous Close $0.577
Change ($) 0.013
Change (%) 2.32%
Day's Open 0.593
Day's Range 0.578 - 0.600
Day's Volume 1,303,012
52-Week Range 0.355 - 1.130

More Stats

Market Cap 135.26M
Enterprise Value 46.31M
Earnings Date (est) Sep 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 229.26M
Float 211.66M
EPS (basic) 0.19
EPS (diluted) 0.15
FCF / Share 0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield 25.42%
FCF Yield 29.86%
Payout Ratio n/a
Shares Short 11.07M
Short Ratio 2.85
Short % of Float 4.89%
Beta 1.55
PE Ratio 3.93
Forward PE n/a
P/FCF Ratio 3.35
PS Ratio 2.24
PB Ratio 1.52
Revenue 60.38M
Operating Income 35.97M
Net Income 37.10M
Free Cash Flow 40.39M
Net Cash 88.95M
Net Cash / Share 0.39
Gross Margin 75.26%
Operating Margin 59.57%
Profit Margin 61.40%
FCF Margin 66.90%
ROA 40.48%
ROE 72.21%
ROIC 272.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.17*
(267.80% upside)
Low
1.50
Current: $0.590
High
3.00
Target: 2.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue60.3067.1344.72-12.95-0.010.071.4814.18
Revenue Growth-10.18%50.11%-----85.95%-95%-89.6%-
Gross Profit60.3067.1344.72-12.95-0.010.071.4814.18
Operating Income35.7425.93-10.57-49.25-17.29-15.79-15.59-18.79-13.65-3.01
Net Income35.7724.70-13.33-51.71-17.67-13.93-20.86-17.25-12.82-1.79
Shares Outstanding20819818415712110797.6234.9020.089.86
Earnings Per Share0.160.12-0.07-0.33-0.15-0.13-0.21-0.49-0.64-0.18
EPS Growth33.33%---------
Operating Cash Flow-21.781.7012.88-47.36-13.36-12.21-13.65-15.49-11.03-5.73
Capital Expenditures-0.04-0.02-0.13-0.02--0.01-0.050.480.010.04
Free Cash Flow-21.821.6812.75-47.38-13.36-12.21-13.70-15.01-11.02-5.69
Cash & Equivalents43.5138.0040.459.3827.3012.1824.424.1819.229.34
Total Debt0.336.2814.1219.529.85-0.020.040.080.03
Net Cash / Debt43.1831.7226.33-10.1417.4512.1824.404.1419.149.31
Assets10539.0256.8310.8629.4712.5625.075.3821.1712.39
Liabilities4.1912.0562.0028.4417.272.772.103.552.983.07
Book Value10126.96-5.16-17.5912.209.7922.981.8318.199.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Palatin Technologies, Inc.
Country United States
Employees 18
CEO Carl Spana

Stock Information

Ticker Symbol PTN
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: PTN
IPO Date October 28, 1993

Description

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.